Cargando…

Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study

OBJECTIVE: The ACT-MOVE study assessed the real-world efficacy and safety of s.c. tocilizumab (TCZ-SC), provided as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) over 1 year, in patients with RA and an inadequate response to csDMARD therapy and/or first TNF inhibitor. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacs, John D, Salih, Abdelrazig, Sheeran, Thomas, Patel, Yusuf I, Douglas, Karen, McKay, Neil D, Naisbett-Groet, Barbara, Choy, Ernest
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649953/ https://www.ncbi.nlm.nih.gov/pubmed/31431998 http://dx.doi.org/10.1093/rap/rkz010

Ejemplares similares

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
por: Diamantopoulos, Alex, et al.
Publicado: (2014)

28. Acute gout with normal inflammatory markers in a seropositive rheumatoid arthritis on longstanding tocilizumab.
por: Levasseur, Kirsty, et al.
Publicado: (2017)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
por: Isaacs, John D, et al.
Publicado: (2013)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
por: Nakashima, Yasuharu, et al.
Publicado: (2014)

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
por: Besada, Emilio
Publicado: (2014)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Fatigue in rheumatoid arthritis
por: Choy, Ernest H, et al.
Publicado: (2019)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019)

Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK
por: Stirnadel-Farrant, Heide A., et al.
Publicado: (2023)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
por: Choy, Ernest H., et al.
Publicado: (2017)

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
por: Choy, Ernest, et al.
Publicado: (2021)

Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK
por: Stirnadel-Farrant, Heide A., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice
por: Ahn, Soo Min, et al.
Publicado: (2022)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
por: Yilmaz, Sedat, et al.
Publicado: (2013)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis
por: Babkoor, Doaa, et al.
Publicado: (2022)

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
por: Wakabayashi, Hiroki, et al.
Publicado: (2019)

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
por: Burmester, Gerd R, et al.
Publicado: (2016)

Cardiovascular risk knowledge in patients of South Asian origin living with rheumatoid arthritis: data from India and the UK
por: Kumar, Kanta, et al.
Publicado: (2020)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
por: Dougados, Maxime, et al.
Publicado: (2013)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nf43j3c13i76d0p0jlcuv2rtqt